Mycophenolic Acid (MPA) is a naturally occurring immunosuppressive compound and the active metabolite of mycophenolate mofetil and mycophenolate sodium. It is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH) and suppresses the proliferation of T and B lymphocytes by reducing de novo guanosine nucleotide synthesis.
Mycophenolic Acid is particularly important in pharmaceutical applications involving immunosuppression and organ transplantation. It is used as the pharmacologically active moiety associated with mycophenolate-based medicines.
The compound has the molecular formula C₁₇H₂₀O₆, molecular weight 320.34 g/mol, and CAS Number 24280-93-1.
Mycophenolic Acid is a fungal-derived immunosuppressive agent originally isolated from Penicillium species. Its pharmacological activity results primarily from inhibition of IMPDH, an enzyme required for guanine nucleotide synthesis.
Because activated lymphocytes depend heavily on the de novo pathway for purine synthesis, inhibition of IMPDH results in reduced proliferation of T and B cells.
Mycophenolic Acid is primarily associated with immunosuppressive therapy, particularly in organ-transplantation medicine.
It is the pharmacologically active metabolite responsible for the immunosuppressive activity of mycophenolate-based pharmaceutical products.
Important: On an API page, it is preferable to describe Mycophenolic Acid as an immunosuppressive pharmaceutical ingredient/active metabolite rather than claiming that the standalone API is universally marketed as a finished medicine.
Mycophenolic Acid acts primarily by inhibiting inosine monophosphate dehydrogenase (IMPDH).
IMPDH plays an important role in the de novo synthesis of guanine nucleotides. Inhibition of this pathway reduces the availability of guanosine nucleotides required for DNA and RNA synthesis.
Activated T and B lymphocytes are particularly dependent on this pathway for proliferation. Therefore, inhibition of IMPDH by Mycophenolic Acid suppresses lymphocyte proliferation and contributes to its immunosuppressive effect.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |
| Melting Point | 141–142°C |